Your binder contains too many pages, the maximum is 40.
We are unable to add this page to your binder, please try again later.
This page has been added to your binder.
June 5, 2014
LONDON, 5 June, 2014 —Horizon Discovery Group plc, an AIM listed international life science company supplying research tools and services to organizations engaged in genomics research and the development of personalized medicines, announced its acquisition of the CombinatoRx service business and related assets from Nasdaq listed Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain. Covington & Burling advised Horizon on the transaction.
The new business will become Horizon CombinatoRx Incorporated, a wholly owned subsidiary of Horizon. Horizon CombinatoRx, Inc. will be located in 23,000 sq. ft. of laboratory and office space in Kendall Square, Cambridge, MA, providing a base for future growth of Horizon’s business operations in North America.
The Covington team was led by partner Kristian Wiggert and associate Philip Young, with assistance from Morag Peberdy (intellectual property), Mike Francese (employee benefits), Heather Haberl (real estate) and Rob Heller (tax).